Receive our newsletter – data, insights and analysis delivered to you

Global clinical trials activity increases 9% YoY in Q1 2021

Global clinical trials activity increased by 9% in Q1 2021, when compared with the same quarter in 2020, according to GlobalData.

Industry sponsored trials accounted for a 51.4% share of overall activity in Q1 2021, an increase of 11.2% when compared with Q1 2020.

Non-industry sponsored trials accounted for a 48.6% share of all clinical trials in Q1 2021, marking a decrease of 11.2% when compared with the same period in 2020.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Q1 2021 industry sponsored clinical trials activity by therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2021, accounting for a 29.6% share of all trials.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

This was followed by Infectious Disease with an 18.4% share, Central Nervous System with 13.4%, Metabolic Disorders with 7.4% and Cardiovascular with 6.4%.

In Q1 2020, Oncology led with a 25.4% share, followed by Infectious Disease with 16.9%, Central Nervous System with 13.7%, Respiratory with 10.6%, and Cardiovascular with 8.4%.

Industry sponsored trials: Q1 2021 vs Q1 2020
Therapy Area Q1 2020 Q1 2021 Activity
Oncology 25.4% 29.6% Increase
Infectious Disease 16.9% 18.4% Increase
Central Nervous System 13.7% 13.4% Decrease
Metabolic Disorders 7.7% 7.4% Decrease
Cardiovascular 8.4% 6.4% Decrease
Respiratory 10.6% 5.8% Decrease
Gastrointestinal 6.7% 5.3% Decrease
Immunology 5.1% 5.0% Decrease
Musculoskeletal Disorders 3.7% 3.9% Increase
Dermatology 4.3% 3.3% Decrease
Ophthalmology 2.9% 3.3% Increase
Hematological Disorders 3.6% 3.1% Decrease
Genito Urinary System And Sex Hormones 2.6% 2.2% Decrease
Genetic Disorders 1.3% 1.5% Increase
Women’s Health 2.4% 1.4% Decrease
Ear Nose Throat Disorders 1.8% 1.0% Decrease
Male Health 0.6% 0.8% Increase
Hormonal Disorders 0.6% 0.7% Increase
Mouth and Dental Disorders 0.8% 0.5% Decrease
Nutritional Disorders 0.7% 0.5% Decrease
Non Malignant Disorders 0.1% 0.0% Decrease

 

Most active therapy areas in non-industry sponsored clinical trials

In Q1 2021 the leading therapy area for non-industry sponsored clinical trials was Oncology, accounting for a 27.9% share of all trials.

This was followed Central Nervous System with a 24.7% share, Infectious Disease with 16.7%, Cardiovascular with 9.2%, and Musculoskeletal Disorders with 5.0%.

In Q1 2020, Central Nervous System held the lead in non-industry sponsored clinical trials with a 21.9% share, followed by Infectious Disease with 20.2%, Oncology with 17.9%, Respiratory with 11.7%, and Cardiovascular with 8.8%.

Non-Industry sponsored trials: Q1 2021 vs Q1 2020
Therapy Area Q1 2020 Q1 2021 Activity
Oncology 17.9% 27.9% Increase
Central Nervous System 21.9% 24.7% Increase
Infectious Disease 20.2% 16.7% Decrease
Cardiovascular 8.8% 9.2% Increase
Musculoskeletal Disorders 5.0% 5.0% Decrease
Gastrointestinal 6.3% 4.6% Decrease
Metabolic Disorders 5.8% 4.6% Decrease
Respiratory 11.7% 4.5% Decrease
Immunology 2.9% 3.1% Increase
Women’s Health 5.2% 3.0% Decrease
Hematological Disorders 2.7% 2.9% Increase
Genito Urinary System And Sex Hormones 2.7% 2.5% Decrease
Dermatology 3.3% 1.8% Decrease
Ophthalmology 1.8% 1.8% Decrease
Mouth and Dental Disorders 2.5% 1.7% Decrease
Ear Nose Throat Disorders 1.4% 0.9% Decrease
Hormonal Disorders 0.5% 0.7% Increase
Genetic Disorders 0.5% 0.6% Increase
Nutritional Disorders 0.7% 0.6% Decrease
Male Health 0.7% 0.5% Decrease
Non Malignant Disorders 0.3% 0.4% Increase

 

Asia-Pacific region has the most activity for industry sponsored clinical trials

Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q1 2021 with a 46.8% share, compared with 52.1% in Q1 2020.

North America was the second most active region with a 38.2% share in Q1 2021, up from 32.6% in Q1 2020, followed by Europe with a 29.4% share in Q1 2021, down from 30.5% in Q1 2020.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 83.5% share in industry sponsored clinical trials in Q1 2021, compared with 83.5% in Q1 2020. Multinational trials accounted for 16.5% in Q1 2021, against 16.5% in Q1 2020.

Regional activity for non-industry sponsored clinical trials

Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q1 2021 with a 39.4% share, down from 51.7% in Q1 2020.

North America held the second position with a 27.6% share in Q1 2021, compared with 14.6% in Q1 2020. This was followed by Europe with a 20.3% share in Q1 2021, as against 15.5% in Q1 2020.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies accounted for 98.8% share of non-industry sponsored clinical trials in Q1 2021, compared with 99.1% in Q1 2020. Multinational trials accounted for a 1.2% share in Q1 2021, up from 0.9% in Q1 2020.

Clinical trials by phase in Q1 2021

Phase II trials outnumbered all other studies with a 39.5% share for industry sponsored trials in Q1 2021, compared with 35.8% in Q1 2020.

The share of Phase I trials stood at 31.0% in Q1 2021, down from 32.9% in Q1 2020. Phase III trials increased to 18.1% in Q1 2021, compared with 16.6% in Q1 2020, followed by Phase IV trials with an 11.4% share in Q1 2021, against 14.7% in Q1 2020.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

For non-industry sponsored clinical trials, Phase II activity decreased to a 49.6% share in Q1 2021, compared with 41.5% in Q1 2020.

Phase IV trials were the second most active with a 21.5% share in Q1 2021, compared with 20.7% in Q1 2020. Phase I trials held a 14.5% share in Q1 2021, against 18.4% in Q1 2020, followed by Phase III trials with a 14.4% share in Q1 2021, over 19.5% in Q1 2020.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU